|
|
|
|
|
|
|
||
By
From the * Schering-Plough, Laboratory for Immunological Research, 69571, Dardilly, France; and DNAX, Research Institute, Palo Alto, California 94304
 |
Abstract |
|---|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
DCs (dendritic cells) function as sentinels of the immune system. They traffic from the blood to
the tissues where, while immature, they capture antigens. They then leave the tissues and move
to the draining lymphoid organs where, converted into mature DC, they prime naive T cells.
This suggestive link between DC traffic pattern and functions led us to investigate the chemokine responsiveness of DCs during their development and maturation. DCs were differentiated
either from CD34+ hematopoietic progenitor cells (HPCs) cultured with granulocyte/macrophage colony-stimulating factor (GM-CSF) plus tumor necrosis factor (TNF)-
or from
monocytes cultured with GM-CSF plus interleukin 4. Immature DCs derived from CD34+
HPCs migrate most vigorously in response to macrophage inflammatory protein (MIP)-3, but
also to MIP-1 and RANTES (regulated on activation, normal T cell expressed and secreted).
Upon maturation, induced by either TNF-, lipopolysaccharide, or CD40L, DCs lose their
response to these three chemokines when they acquire a sustained responsiveness to a single
other chemokine, MIP-3
. CC chemokine receptor (CCR)6 and CCR7 are the only known
receptors for MIP-3 and MIP-3, respectively. The observation that CCR6 mRNA expression decreases progressively as DCs mature, whereas CCR7 mRNA expression is sharply upregulated, provides a likely explanation for the changes in chemokine responsiveness. Similarly,
MIP-3 responsiveness and CCR7 expression are induced upon maturation of monocyte-
derived DCs. Furthermore, the chemotactic response to MIP-3 is also acquired by CD11c+
DCs isolated from blood after spontaneous maturation. Finally, detection by in situ hybridization of MIP-3 mRNA only within inflamed epithelial crypts of tonsils, and of MIP-3
mRNA specifically in T cell-rich areas, suggests a role for MIP-3/CCR6 in recruitment of
immature DCs at site of injury and for MIP-3/CCR7 in accumulation of antigen-loaded mature DCs in T cell-rich areas.
| |
Introduction |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Dendritic cells (DCs)1 are professional APCs that are found in all lymphoid and nonlymphoid organs (1). DCs are bone marrow-derived and likely migrate as precursors through blood stream to tissues, where they become resident cells such as Langerhans cells in the epidermis. Moreover, after pathogen invasion, DCs are probably recruited at the site of inflammation (2), as illustrated in the rat, where intratracheal antigen instillation induces accumulation of DCs in the airway epithelium (3). In the periphery, DCs such as Langerhans cells capture the antigens (4), then migrate via the lymphatics and home to the T cell-rich area of lymph nodes, where they are called interdigitating cells (IDCs) (9). At this site, they present the processed antigens to naive T cells and generate an antigen-specific primary T cell response (15). During their migration from peripheral tissues to lymphoid organs, DCs undergo a maturation process encompassing dramatic changes in phenotype and functions (11, 19, 20). In particular, immature DCs such as fresh Langerhans cells capture and process soluble proteins efficiently and are effective at activating specific memory and effector T cells. Conversely, mature DCs such as IDCs of lymphoid organs are poor in antigen capture and processing but markedly efficient in naive T cell priming (4, 21, 22). This last difference correlates with the levels of expression of MHC class II and accessory molecules such as B7, which are much higher on mature than on immature DCs (23).
Although signals regulating the complex traffic pattern of
DCs are not fully understood, chemokines are probably
involved. Chemokines are small molecular mass proteins
(8-10 kD) that regulate leukocyte migration and activation
(28). They are secreted by activated leukocytes themselves
and by stromal cells, including endothelial cells and epithelial
cells upon inflammatory stimuli (28). Responses to
chemokines are mediated by seven transmembrane-spanning G protein-coupled receptors (30, 32, 33). Several chemokines such as monocyte chemotactic protein (MCP)-3, MCP-4,
macrophage inflammatory protein (MIP)-1, MIP-1,
RANTES (regulated on activation, normal T cell expressed
and secreted), stromal cell-derived factor (SDF)-1, thymus-expressed chemokine ( Teck), and macrophage-derived chemokine have been reported to attract DCs in vitro (34).
Moreover, signals provided by TNF- and LPS are known
to induce in vivo migration of resident DCs from the
tissues to the draining lymphoid organs (20, 37).
However, the relationship between signals inducing DC
migration in vivo and their responses to chemokines is not
known.
In this study, we have taken advantage of the well-established control of CD34+ hematopoietic progenitor cell (HPC; 41-43) and monocyte (22, 44) cultures to study the chemokine responsiveness of DCs during their differentiation and maturation. Focusing on CC chemokine receptor (CCR)6 (45) and CCR7 (49) and their known ligands (47, 50), we found that chemokine receptor expression and the subsequent chemokine responsiveness are indeed integral parts of the maturation process of DCs. In addition, in situ localization of chemokines active on immature versus mature DCs provides a likely explanation for at least part of the DC traffic pattern.
| |
Materials and Methods |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Hematopoietic Factors, Reagents, and Cell Lines.
Recombinant human (rh)GM-CSF (specific activity: 2 × 106 U/mg; Schering-Plough Research Institute, Kenilworth, NJ) was used at a saturating concentration of 100 ng/ml. rhTNF- (specific activity: 2 × 107 U/mg; Genzyme, Boston, MA) was used at an optimal concentration of 2.5 ng/ml (42). rhSCF (specific activity: 4 × 105 U/mg,
R&D Systems, Abington, UK) was used at an optimal concentration of 25 ng/ml. rhIL-4 (specific activity: 2 × 107 U/mg, Schering-Plough Research Institute) was used at a saturating concentration of 50 U/ml. Recombinant human chemokines MIP-1 (specific activity: 2 × 105 U/mg, 9 × 1012 U/M), RANTES
(specific activity: 104 U/mg, 8 × 1010 U/M), MIP-3 (specific
activity: 4 × 105 U/mg, 3 × 1012 U/M) and MIP-3 (specific
activity: 104 U/mg, 9 × 1010 U/M) were obtained from R&D
Systems. LPS was used at 10 ng/ml (Sigma Chemical Co., St.
Louis, MO).
The murine CD40 ligand transfected cell line (CD40L L cells)
was produced in the laboratory and used as stimulator of DC
maturation (53).
Generation of DCs from Cord Blood CD34+ HPCs.
Umbilical cord blood samples were obtained after full-term delivery. Cells bearing CD34+ antigen were isolated from mononuclear fractions through positive selection as previously described (42, 54), using anti-CD34+ mAb (Immu-133.3, Immunotech, Marseille, France), goat anti-mouse IgG-coated microbeads (Miltenyi Biotec GmBH, Bergisch Gladbach, Germany), and Minimacs separation columns (Miltenyi Biotec GmBH). In all experiments the isolated cells were 80-99% CD34+. After purification, CD34+ cells were cryopreserved in 10% DMSO. Cultures were established in the presence of stem cell factor, GM-CSF, and TNF- as previously described (42) in endotoxin-free medium consisting of RPMI 1640 (GIBCO BRL, Gaithersburg, MD) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Life Technologies, Pontoise, France), 10 mM
Hepes, 2 mM L-glutamine, 5 × 10
5 M -mercaptoethanol, and
100 µg/ml gentamycin (Schering-Plough, Levalois, France) (referred to as complete medium). After thawing, CD34+ cells were
seeded for expansion in 25-75 cm2 culture vessels (Linbro; ICN
Biomedicals, Aurora, OH) at 2 × 104 cells/ml. Optimal conditions were maintained by splitting these cultures at days 5 and 10 with medium containing fresh GM-CSF and TNF- (cell concentration: 1-3 × 105 cells/ml). At day 12, between 70 and 90%
of the cells were CD1a+ DCs.
Isolation of Immature and Mature DCs According to CD86 Expression by FACS® Sorting.
After 12 d of culture in the presence of GM-CSF and TNF-, cells were collected and labeled with
FITC-conjugated OKT6 (CD1a; Ortho Diagnostic System, Raritan, NJ) and PE-conjugated IT2.2 (CD86; PharMingen, San Diego,
CA). Cells were separated according to CD1a and CD86 expression into immature CD1a+CD86 and mature CD1a+CD86+
DC populations using a FACStarplus® (laser setting: power 250 mW, excitation wavelength 488 nm; Becton Dickinson, Sunnyvale, CA). All the procedures of staining and sorting were performed in presence of 0.5 mM EDTA to avoid cell aggregation.
Reanalysis of the sorted populations showed a purity >98%.
Generation of DCs from Peripheral Blood Monocytes.
Monocyte s were purified by immunomagnetic depletion (Dynabeads; Dynal, Oslo, Norway) after preparation of PBMCs followed by a 52% Percoll gradient. The depletion was performed with anti-CD3 (OKT3), anti-CD19 (4G2), anti-CD8 (OKT8), anti-CD56 (NKH1, Coulter Corp., Hialeah, FL), and anti-CD16 (ION16, Immunotech) mAbs. Monocyte-derived dendritic cells were produced by culturing purified monocytes for 6-7 d in the presence of GM-CSF and IL-4 (44).Induction of Maturation of In Vitro-generated DCs.
CD34+ HPCs were cultured until day 6 in presence of GM-CSF plus TNF-
and in presence of GM-CSF alone from days 6 to 12 in order to
preserve their immaturity. Immature DCs from CD34+ HPCs or
monocyte-derived DCs were activated for 3-72 h in the presence
of TNF- (2.5 ng/ml), LPS (10 ng/ml), or CD40L transfected L
cells (one L cell for five DCs) as described elsewhere (55).
Purification of CD11c+ DCs from Peripheral Blood or Tonsils.
CD11c+ DCs were prepared as previously described from peripheral blood or tonsils (56). In brief, tonsils obtained from children undergoing tonsillectomy were finely minced and digested with collagenase IV and DNase I (Sigma Chemical Co.). The collected cells were centrifuged through Ficoll-Hypaque with SRBCs (BioMérieux, Lyon, France) for 15 min at 500 rpm, then for 30 min at 2,000 rpm. Mononuclear cells from peripheral blood were isolated by Ficoll-Hypaque. CD3+ T cells (OKT3), CD19+ B cells (4G7), and CD14+ monocytes (MOP9) were removed from the resulting low density cells by magnetic beads (anti-mouse Ig-coated Dynabeads [Dynal]). A second depletion was performed with anti-NKH1, anti-glycophorine A (Immunotech), and anti-CD20 (1F54). The remaining cells were stained with the following mAbs: anti-CD1a FITC (OKT6); anti-CD14 FITC, anti-CD57 FITC, anti-CD16 FITC, anti-CD7 FITC, anti-CD20 FITC, anti-CD3 FITC (Becton Dickinson); anti-CD4 PE-Cy5 (Immunotech), and anti-CD11c PE (Becton Dickinson). CD4+CD11c+lineage DCs were isolated by cell sorting
using a FACStarPlus® (laser setting: power 250 mW, excitation
wavelength 488 nm). All the procedures of depletion, staining,
and sorting were performed in presence of 0.5 mM EDTA. Reanalysis of the sorted population showed a purity >97%.
Chemotaxis Assay.
Cell migration was evaluated using a chemotaxis microchamber technique (48-well Boyden microchamber; Neuroprobe, Pleasanton, CA; reference 57). In brief, MIP-3 and MIP-3, MIP-1, and RANTES were diluted to
concentrations ranging from 1 to 1,000 ng/ml in RPMI 1640 medium, and were added to the lower wells of the chemotaxis
chamber. 105 cells/well (or 5 × 104 cells/well for CD11c+ DCs)
in 50 µl of RPMI 1640 medium were applied to the upper wells of the chamber, with a standard 5-µm pore polyvinylpyrrolidone-free polycarbonate filter (Neuroprobe) separating the lower
wells. The chamber was incubated at 37°C in humidified air with
5% CO2 for 1 h. Then, cells that had migrated to the underside of
the filter were stained with Field's A and Field's B (BDH Chemicals, Ltd., Abingdon, Essex, UK) and counted using an image analyzer (software: Vision Explorer and ETC 3000; Graphtek, Mirmande, France) in two randomly selected low power fields
(magnification: ×20). Each assay was performed in duplicate and
the results were expressed as the mean ± SD of migrating cells
per two fields.
Extraction of Total RNA and Synthesis of cDNA.
Cells were prepared as described above, and total RNA was extracted by the guanidinium thiocyanate method as mentioned by the manufacturer (RNAgents total RNA isolation system; Promega, Madison, WI). After DNAse I treatment (RQ1 RNAse free DNAse; Promega), RNA was quantified by spectrophotometry and quality was evaluated by electrophoresis in formaldehyde denaturing conditions. First strand cDNA was synthetized from total RNA extracted in RNAse-free conditions. The reaction was performed with 5 µg of total RNA, 25 ng/µl oligo dT12-18 primers (Pharmacia, Orsay, France) and the Superscript kit (SuperScript II RNase H Reverse Transcriptase; GIBCO BRL), as described by
the manufacturer. For all samples, synthesis of cDNA was controlled and calibrated by reverse transcriptase (RT)-PCR using
-actin primers for 21 cycles.
RT-PCR Analysis.
Semi-quantitative PCR was performed in a Perkin Elmer 9,600 thermal cycler, in a final volume of 100 µl reaction mixture containing 2.5 U AmpliTaq enzyme (5 U/µl, Perkin Elmer, Paris, France) with its 1× buffer, 0.2 mM of each dNTP (Perkin Elmer), 5% DMSO, and 1 µM of each forward and reverse primer. CCR6 and CCR7 primers (sequence data available from EMBL/GenBank/DDBJ under accession numbers Z79784 and L08176, respectively) were designed within regions of lowest homology between the chemokine receptors. +80/ CCR6 5'-ATTTCAGCGATGTTTTCGACTC-3' forward primer,
1081/CCR6 5'-GGAGAAGCCTGAGGACTTGTA-3' reverse primer, +154/CCR7 5'-GATTACATCGGAGACAACACC-3' forward primer and 1202/CCR7 5'-TAGTCCAGGCAGAAGAGTCG-3' reverse primer were used for
RT-PCR and sequencing. For both chemokine receptors, the
reaction mixture was subjected to 30 and 35 cycles of PCR with
the following conditions: 94°C for 1 min, 61.5°C for 2 min, and
72°C for 3 min. PCR products were visualized on 1.2% agarose gels containing 0.5 µg/ml ethidium bromide. Reaction products migrating at the predicted size (1,021 bp for CCR6 and 1,067 bp for CCR7) were gel purified and subcloned into pCRII TA
cloning vector (Invitrogen, Leek, The Netherlands) for sequencing verification on an ABI 373A Sequencer (Applied Biosystems,
Inc., Foster City, CA) using dye terminator technology. Two
other oligonucleotides, 622/CCR6 5'-GCTGCCTTGGGTGTTGTATTT-3' and +662/CCR7 5'-AGAGGAGCAGCAGTGAGCAA-3', were used as probes for hybridization with the
PCR products separated on 1.2% agarose gel and blotted onto
Hybond N+ membranes (Amersham, Les Ulis, France).
Calcium Fluorimetry.
Intracellular Ca2+ concentration was measured using the fluorescent probe Indo-1, according to the technique reported by Grynkiewicz et al. (58). In brief, cells were washed in PBS and resuspended at 107 cells/ml in complete RPMI 1640 medium (see above). Then, cells were incubated for 45 min at room temperature with 3 µg/ml Indo-1 AM (Molecular Probes, Inc., Eugene, OR) in the dark. After incubation, cells were washed and resuspended in HBSS/1% FCS at 107 cells/ml. Before measurement of intracellular Ca2+ concentration, cells were diluted 10-fold in HBSS/10 mM Hepes/1.6 mM CaCl2 preheated at 39°C. Samples were excited at 330 nm with continuous stirring and the Indo-1 fluorescence was measured as a function of time at 405 nm (dye is complexed with Ca2+) and 485 nm (Ca2+-free medium) in a 810 Photomultiplier Detection System (software: Felix; Photon Technology International, Monmouth Junction, NJ). Results are expressed as the ratio of values obtained at the two emission wavelengths.In Situ Hybridization.
In situ hybridization was performed as previously described (59). Two-couple primers were used for amplifying by RT-PCR the majority of the open reading frame of MIP-3 and MIP-3 genes (sequence data available from
EMBL/GenBank/DDBJ under accession numbers D86955 and
U77180, respectively). +77/MIP-3 5'-TTGCTCCTGGCTGCTTTG-3' forward primer and 425/MIP-3 5'-ACCCTCCATGATGTGCAAG-3' reverse primer, +25/MIP-3 5'-CTGCTGGTTCTCTGGACTTC-3' forward primer and 439/
MIP-3 5'-CACACTCACACTCACACACAC-3' reverse primer
were used as described above with an annealing temperature at
62°C. Then, PCR products were cloned into pCRII TA cloning
vector (Invitrogen) for the generation of sense and antisense
probes with the adapted promoters. Sense and antisense 35S-labeled
probes of MIP-3 and MIP-3 were obtained by run off transcription of the 367-bp and 435-bp fragments, respectively. 6-µm
human tonsil sections were fixed in acetone and 4% paraformaldehyde followed by 0.1 M triethanolamine/0.25% acetic
anhydride. The sections were hybridized overnight, RNAse A
treated and exposed for 24 d. After development sections were
stained with hematoxylin.
| |
Results |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
and MIP-3 during
Development of CD34+-derived DCs.
As a way to understand the regulation of DC traffic, we have studied the response to various chemokines of DCs at different stages of
maturation. DCs were generated from CD34+ HPCs cultured in the presence of GM-CSF plus TNF-, and tested at different days of culture for their ability to migrate in response to chemokines in Boyden microchambers. MIP-3
and MIP-3 recruited two to three times more CD34+-derived DCs than did MIP-1 or RANTES (Fig. 1 A,
mean of 20 experiments). However, MIP-3 and MIP-3
attracted DCs collected at different time points of the culture (Fig. 1 B). The response to MIP-3 was already detectable at day 4, maximal at days 5-6, and lasted until day
10. At days 13-14, the response to MIP-3 was usually lost. In contrast, the response to MIP-3, which could not
be detected before day 10, peaked at day 13, and persisted
beyond day 15 (data not shown). Of note, at early time
points (Fig. 2, Day 6), when most of the cells in culture
were still DC precursors (CD1aCD86), the response to
MIP-3 could be detected at concentrations of 1-10 ng/ml
(depending on the experiment). In contrast, 4 d later, when
almost all cells were immature DCs (CD1a+CD86), 
300
ng/ml were needed to attract the cells (Fig. 2, Day 10), suggesting a progressive desensitization of the cells during
maturation. Relatively high concentrations of MIP-3
(300 ng/ml) were also needed to recruit mature DCs
(CD1a+CD86+) (Fig. 2, Day 13). Checkerboard analysis
established that MIP-3 and MIP-3 induced chemotaxis
and not chemokinesis of DCs (data not shown).
|
|
To confirm the relation between the stage of maturation
and the response to MIP-3 and MIP-3, CD34+-derived
DCs were FACS® sorted at day 10 of culture according to
CD86 expression into immature DCs (CD1a+CD86) and
mature DC (CD1a+CD86+). CD1a+CD86 responded
exclusively to MIP-3, whereas CD1a+CD86+ responded
mainly to MIP-3 (Fig. 3). These observations also confirmed that the cells recruited by MIP-3 and MIP-3
were indeed DCs (CD1a+). The correlation between DC
maturation and chemokine responsiveness was further illustrated when the immaturity of DCs was preserved by removing TNF- from days 6 to 12 and when their maturation was synchronized by addition of TNF-, LPS, or
CD40L. As shown in Fig. 4 A, response to MIP-3 had
strongly decreased after 48 h of maturation with TNF-,
LPS, and CD40L. Meanwhile, the response to MIP-3
was induced by all three signals, CD40L and LPS being more potent than TNF-. In kinetics experiments, the response to MIP-3 decreased by 50-70% after only 24 h of
CD40 activation and was completely lost at 72 h. The response to MIP-3 was already maximal after 24 h of CD40
activation (Fig. 4 B) and required relatively high concentration of chemokine (100-300 ng/ml) at 48 h (Fig. 4 C).
|
|
Taken together, these results establish that immature
CD34+-derived DCs respond to MIP-3, whereas mature
DCs respond to MIP-3.
and MIP-3 Parallel the Expression of
Their Respective Receptors, CCR6 and CCR7, on CD34+-derived
DCs.
To define the mechanisms of regulation of MIP-3
and MIP-3 responsiveness, the expression of their respective receptors, CCR6 (45) and CCR7 (49) mRNA,
was studied by semi-quantitative RT-PCR. During DC
development from CD34+ HPCs, CCR6 mRNA was first
detected at day 6 and increased up to day 10, after which it
decreased and became barely detectable at day 14. In contrast, CCR7 mRNA appeared at day 10 and steadily increased
up to day 14 (Fig. 5 A). Moreover, CD40L-dependent
maturation induced progressive downregulation of CCR6
mRNA that became almost undetectable after 72 h, and
upregulation of CCR7 mRNA as early as 24 h after (Fig. 5
B). Similar results were obtained after either LPS- or TNF--induced DC maturation (data not shown). The upregulation of CCR7 mRNA after activation was confirmed by
Southern blot analysis of cDNA libraries (data not shown).
|
In line with the migration assays and the regulation of
CCR6 and CCR7 expression, MIP-3 induced a Ca2+
flux exclusively in resting/immature DC (Fig. 6 A), and
MIP-3 induced the same in mature DCs only (independently of the maturation signal, CD40 activation is shown
on Fig. 6 B). Maximal Ca2+ fluxes were observed with 30 ng/ml of MIP-3 and 30 ng/ml of MIP-3, on immature
and mature DCs, respectively (Fig. 6, C and D).
|
These results show that changes in responsiveness to
MIP-3 and MIP-3 are linked to the regulation of
CCR6 and CCR7 mRNA expression, and suggest that
CCR6 and CCR7 are the major functional receptors expressed on DCs for MIP-3 and MIP-3, respectively.
Is Also Induced upon Maturation of
Monocyte-derived DCs.
Monocyte-derived DCs, generated
by culturing monocytes in presence of GM-CSF+IL-4
for 6 d, are typically immature DCs (CD1a+, CD14,
CD80low, CD86low, and CD83) (22, 44). They migrated
in response to MIP-1 and RANTES but not to MIP-3
(data not shown) or MIP-3 (Fig. 7). The lack of response
of monocyte-derived DCs to MIP-3 is in accordance with the absence of CCR6 expression on those cells (45,
46). Upon maturation induced by TNF-, LPS, or CD40L,
responses to MIP-1 and RANTES were lost, whereas response to MIP-3 was induced (Fig. 7, A and B). As with
CD34+-derived DCs, the response to MIP-3 correlated
with the upregulation of CCR7 mRNA expression observed upon maturation induced by TNF- (Fig. 8 A),
LPS (data not shown), or CD40L (Fig. 8 B). Again, upregulation of CCR7 occurred at early time points (3 h) after TNFR or CD40 signaling. Moreover, migration and
chemokine receptor expression data were in agreement
with Ca2+ flux results (data not shown).
|
|
Those results extend to monocyte-derived DCs the concept that upon maturation, DCs lose their responsiveness to
various chemokines while becoming sensitive to a single
chemokine, MIP-3.
after Maturation.
We next studied the chemotactic activities of MIP-3 and MIP-3 on immature
CD11c+ DCs isolated from peripheral blood (or tonsils).
Freshly isolated DCs did not migrate in response to MIP-3,
or to MIP-3 (Fig. 9 A), an observation that correlates
with the absence of CCR6 (data not shown) and CCR7
mRNA expression in these cells (Fig. 9 B). However, the
maturation that is known to occur after overnight culture
with GM-CSF (56) turned on the response of CD11c+ DC
to MIP-3 but not to MIP-3. Once more, the response
to MIP-3 correlated with the induction of CCR7
mRNA expression (Fig. 9 B).
|
Therefore, although immature CD11c+ DCs freshly isolated from blood cannot respond to MIP-3, these results
show that maturation-dependent responsiveness to MIP-3
also applies to ex vivo-isolated DCs.
Is Expressed in Inflamed Epithelium and
MIP-3 within T Cell-rich Areas of Tonsils.
The physiological relevance of these findings was then addressed through
the analysis of MIP-3 and MIP-3 mRNA expressions by
in situ hybridization on sections of inflamed tonsils.
mRNA for MIP-3 was detected at high levels in inflamed
epithelial crypts but not in T cell-rich areas or in B cell follicles (Fig. 10, A-C). In fact, MIP-3 expression was restricted to cells lining the epithelial crypts (Fig. 10 D). In
contrast, expression of MIP-3 mRNA was restricted to T
cell-rich areas (Fig. 10, F-H). The strongest signal was
present in scattered cells, with a distribution overlapping that of IDCs (Fig. 10, F-I). Outside the paracortical area,
no signal could be detected in B cell follicles or in epithelial crypts (Fig. 10, F-H). Fig. 10, A and F (serial sections),
shows clear absence of MIP-3 expression within epithelial
crypts where MIP-3 was abundantly present. Sense
probes for MIP-3 and MIP-3 did not generate background hybridization (Fig. 10, E and J).
|
Therefore, MIP-3 expression is restricted to inflamed
epithelium at the site of antigen entry, where immature
DCs should be recruited. In contrast, MIP-3 is only detected in paracortical areas, where mature IDCs home and
generate primary T cell responses.
| |
Discussion |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Chemokine responsiveness appears to be one important
functional feature that characterizes the stage of DC maturation. Immature DCs respond to MIP-3, RANTES, and
MIP-1. Upon maturation, DCs lose their responsiveness
to these chemokines to become sensitive to a single
chemokine, MIP-3.
Taking advantage of culture conditions that tightly control DC maturation, we have found that immature DCs,
which very efficiently capture and process the antigens, migrate in response to MIP-1, RANTES, and MIP-3, in
line with previous reports (34, 45). But in agreement
with recent observations (60), mature DCs that have lost
their aptitude to internalize antigens (21, 44, 61) cannot be
recruited by these chemokines anymore. However, along
with the ability to prime naive T cells, they have acquired responsiveness to MIP-3. Furthermore, microenvironmental signals, like TNF- and LPS, or T cell signals, such
as CD40L, induce loss of response to MIP-3, MIP-1,
and RANTES and acquisition of response to MIP-3.
These same signals induce DC maturation characterized by
a rapid loss of antigen uptake capacities (21, 44, 62, 63).
The link between DC maturation and migration pattern is further supported by the observation that the same signals,
such as TNF- and LPS that induce DC maturation in
vitro, also trigger migration in vivo (20, 37). Thus, the
modulation of chemokine responsiveness is part of a coordinated regulation of functions that defines the stage of DC
maturation. Such a connection between maturation/activation and chemokine responsiveness is not unique to DCs.
In particular, resting and activated (64) or naive and memory (65, 66) T cells are not recruited by the same chemokines. Also memory and naive B cells respond to stromal
cell-derived factor (SDF)-1, whereas germinal center B
cells do not (67). Altogether, these observations suggest
that the recruitment of immune cells in vivo would be dependent on their stages of development and maturation/activation.
The mechanism underlying the modulation of chemokine responsiveness during activation/maturation of DC
includes the regulation of the chemokine receptor expression. Therefore, the change in expression levels of CCR6
and CCR7 contributes to the functional shifts characterizing DC maturation. Other molecules linked to function are
also regulated, particularly molecules involved in antigen
uptake (Fc receptors, mannose receptors, and other lectins) or skin homing (E-cadherin), which are downregulated upon
maturation. In contrast, molecules involved in migration
(matrix metalloproteases [our observations]), in antigen
presentation (MHC class II, protease/protease inhibitor,
DC-LAMP [de Saint Vis, B., manuscript in preparation), in
costimulation (CD80, CD86) (68) or in T cell commitment (IL-10, IL-12) (69) are upregulated. CCR6 gene expression is progressively downregulated on CD34+-derived
DCs after activation/maturation with TNF-, LPS, or
CD40L. The downregulation of CCR6 mRNA expression
upon DC activation is in line with a previous study showing downregulation of CCR1, CCR2, and CCR5 mRNA
on monocytes after TNF- or LPS activation (70). Also,
on T cells, CD3 activation induces a rapid loss of CCR1
and CCR2 (64) and PHA activation induces downregulation of CCR6 (47). However, in addition to the downregulation of CCR6 mRNA expression, which is not completely extinct on mature DCs, other mechanisms might be
involved in the loss of MIP-3 responsiveness (31). Signals
inducing maturation might directly interfere with CCR6
signalization or indirectly cause CCR6 desensitization through engagement by endogenous MIP-3, which is effectively produced by DCs upon CD40 activation (our observations).
In contrast to CCR6, CCR7 mRNA, absent on immature DCs, is induced upon maturation and the rapidity of this induction (detected within 3 h) probably reflects a direct effect of DC activation through CD40 or TNFR. Similar activation-dependent upregulation of CCR7 had been previously reported on T and B cells (71, 72). In this context, CCR7 expression is also induced on B and T cells after EBV infection (72) or herpesvirus infection (73), respectively. Furthermore, the expression of other receptors is activation-dependent. In particular, on T cells, expression of CCR1, CCR2A, and CCR2B is IL-2 dependent (64), and CXCR4 expression is induced by PHA activation (66). In addition, IL-2 increases the response of NK cells to chemokines (74, 75).
Most of the known chemokines bind several receptors.
However, with regards to the correlation between the migration profiles, the expression of chemokine receptors,
and Ca2+ flux responses, it is likely that CCR6 and CCR7
are the major functional receptors for MIP-3 and MIP-3, respectively, expressed on DCs. MIP-3 response was
observed on immature CD34+-derived DCs, but not on
monocyte-derived DCs, in line with absence of CCR6 expression (45, 46). The reason for this lack of CCR6 expression is under investigation and might reflect either that monocyte-derived DCs represent a different DC subset, or
that IL-4 blocks CCR6 expression.
Although MIP-3 appears as the most potent chemokine in inducing migration of immature CD34+-derived
DCs, the DC population responding to MIP-3 in vivo
has not yet been identified. Immature CD11c+ blood DCs
are unresponsive, but Langerhans cells or their direct precursors (CD34+CLA+; reference 76) represent potential
target populations. In this regard, precursor cells (days 4-6
of culture) are responsive to low concentrations of MIP-3
(1-10 ng/ml) compared with their more differentiated but
still immature progenies (day 10 of culture). In contrast, the
response to MIP-3 appears to be a general feature of mature
DCs, including monocyte-derived and CD11c+ blood DCs.
The biological activities of MIP-3 and MIP-3 on
other immune cells have been poorly characterized thus
far. MIP-3 and MIP-3 have been shown to induce arrest of lymphocytes rolling under flow conditions, MIP-3
acting mainly on memory CD4 T cells and MIP-3 on
most lymphocytes (77). Furthermore, MIP-3 induces migration of T cells but is inactive on monocytes and neutrophils (reference 45 and our observations) and MIP-3 attracts T and B lymphocytes but not granulocytes and
monocytes (78).
Regarding in vivo expression, MIP-3 mRNA is mainly
expressed in lung, appendix, liver, and some lymphoid organs (47, 50) and by many cell types both of hematopoietic and nonhematopoietic (fibroblasts, keratinocytes,
endothelial cells) origins (47, 50-52, and our observations).
Moreover, the production of MIP-3 is induced by inflammatory stimuli such as LPS or TNF- by endothelial
cells and monocytes (50, 52, and our observations). Now,
we show by in situ hybridization that MIP-3 is expressed
in tonsil by inflamed epithelium, a site known to be infiltrated by immature DCs. In contrast, the expression of
MIP-3 mRNA is restricted to lymphoid organs and to
cells of hematopoietic origin, in particular DCs as well as B
lymphocytes and monocytes (49, 52, and our observations). In tonsil, MIP-3 mRNA as detected by in situ hybridization, is expressed by scattered cells within T cell-rich areas
where mature IDCs home.
Thus, it is tempting to speculate that upon local injury,
immature DCs or their precursors, expressing CCR6,
would be attracted to the site of inflammation through the
local production of chemokines like MIP-3. Such accumulation of DCs has been observed in the airway epithelium of rat after intratracheal antigen instillation (3). After
antigen uptake, TNF-- or LPS-induced maturation would
turn off MIP-3 responsiveness, thereby enabling emigrating DCs to escape the local gradient of MIP-3. Simultaneous acquisition of CCR7 would drive maturing DCs
into the paracortical area of lymphoid organs in response to
the production of MIP-3 by cells spread over the T cell
zone. As MIP-3 can attract mature DCs and lymphocytes
(77, 78), it is likely to play a key role in helping antigen-loaded DCs to meet specific T cells.
| |
Footnotes |
|---|
Address correspondence to Christophe Caux, Schering-Plough, 27 chemin des Peupliers, BP 11, 69571, Dardilly, France. Phone: 33-4-72-17-27-00; Fax: 33-4-78-35-47-50; E-mail: christophe.caux{at}sch-plough.fr
Received for publication 31 March 1998.
M.C. Dieu is recipient of a grant from Fondation Marcel Mérieux, Lyon, France.We are grateful to I. Durand and E. Garcia for FACS® sorting; C. Massacrier for cell purification; T. Schall and J. Hedrick for scientific and technical expertise, S. Bourdarel and M. Vatan for editorial assistance; D. Lepot for the setting of the image analyzer and of the spectrofluorimeter; and the doctors and colleagues from clinics and hospitals in Lyon who provided us with umbilical cord blood samples and tonsils. We would like to address a special dedication to express all our gratitude to Dr. J. Chiller for his support in this specific project.
Abbreviations used in this paper CCR, CC chemokine receptor; DC, dendritic cell; HPC, hematopoietic progenitor cell; IDC, interdigitating cell; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; RANTES, regulated on activation, normal T cell expressed and secreted; rh, recombinant human; RT, reverse transcriptase.
| |
References |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
| 1. | Steinman, R.M.. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296 [Medline]. |
| 2. |
Kaplan, G.,
G. Walsh,
L.S. Guido,
P. Meyn,
R.A. Burkhardt,
R.M. Abalos,
J. Barker,
P.A. Frindt,
T.T. Fajardo,
R. Celona, and
Z.A. Cohn.
1992.
Novel responses of human skin
to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.
J. Exp. Med.
175:
1717-1728
|
| 3. |
McWilliam, A.S.,
D. Nelson,
J.A. Thomas, and
P.G. Holt.
1994.
Rapid dendritic cell recruitment is a hallmark of the
acute inflammatory response at mucosal surfaces.
J. Exp. Med.
179:
1331-1336
|
| 4. |
Inaba, K.,
G. Schuler,
M.D. Witmer,
J. Valinksy,
B. Atassi, and
R.M. Steinman.
1986.
Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for
stimulation of unprimed and sensitized T lymphocytes.
J.
Exp. Med.
164:
605-613
|
| 5. | Streilein, J.W., and S.F. Grammer. 1989. In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes. J. Immunol. 143: 3925-3933 [Abstract]. |
| 6. |
Romani, N.,
S. Koide,
M. Crowley,
M. Witmer-Pack,
A.M. Livingstone,
C.G. Fathman,
K. Inaba, and
R.M. Steinman.
1989.
Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact Protein is presented best by
immature, epidermal Langerhans cells.
J. Exp. Med.
169:
1169-1178
|
| 7. |
Puré, E.,
K. Inaba,
M.T. Crowley,
L. Tardelli,
M.D. Witmer-Pack,
G. Ruberti,
G. Fathman, and
R.M. Steinman.
1990.
Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of MHC class II molecules and expression of invariant chain.
J. Exp. Med.
172:
1459-1469
|
| 8. |
Schuler, G., and
R.M. Steinman.
1985.
Murine epidermal
Langerhans cells mature into potent immunostimulatory dendritic cells in vitro.
J. Exp. Med.
161:
526-546
|
| 9. |
Austyn, J.M.,
J.W. Kupiec-Weglinski,
D.F. Hankins, and
P.J. Morris.
1988.
Migration patterns of dendritic cells in the
mouse. Homing to T cell-dependent areas of spleen, and
binding within marginal zone.
J. Exp. Med.
167:
646-651
|
| 10. |
Kupiec-Weglinski, J.W.,
J.M. Austyn, and
P.J. Morris.
1988.
Migration patterns of dendritic cells in the mouse. Traffic
from blood, and T cell-dependent and independent entry to
lymploid tissues.
J. Exp. Med.
167:
632-645
|
| 11. |
Larsen, C.P.,
R.M. Steinman,
M.D. Witmer-Pack,
D.F. Hankins,
P.J. Morris, and
J.M. Austyn.
1990.
Migration and
maturation of Langerhans cells in skin transplants and explants.
J. Exp. Med.
172:
1483-1494
|
| 12. | Fossum, S.. 1988. Lymph-borne dendritic leukocytes do not recirculate, but enter the lymph node paracortex to become interdigitating cells. Scand. J. Immunol. 27: 97-105 [Medline]. |
| 13. |
Macatonia, S.E.,
S.C. Knight,
A.J. Edwards,
S. Griffiths, and
P. Fryer.
1987.
Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein
isothiocyanate.
J. Exp. Med.
166:
1654-1667
|
| 14. | Kripke, M.L., C.G. Munn, A. Jeevan, J.-M. Tang, and C. Bucana. 1990. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145: 2833-2838 [Abstract]. |
| 15. |
Inaba, K.,
J.P. Metlay,
M.T. Crowley, and
R.M. Steinman.
1990.
Dendritic cells pulsed with protein antigens in vitro can
prime antigen-specific, MHC-restricted T cells in situ.
J.
Exp. Med.
172:
631-640
|
| 16. |
Liu, L.M., and
G.G. MacPherson.
1993.
Antigen acquisition
by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo.
J. Exp.
Med.
177:
1299-1307
|
| 17. |
Sornasse, T.,
V. Flamand,
G. De Becker,
H. Bazin,
F. Tielemans,
K. Thielemans,
J. Urbain,
O. Leo, and
M. Moser.
1992.
Antigen-pulsed dendritic cells can efficiently induce an
antibody response in vivo.
J. Exp. Med.
175:
15-21
|
| 18. |
Heufler, C.,
F. Koch, and
G. Schuler.
1988.
Granulocyte/
macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells
into potent immunostimulatory dendritic cells.
J. Exp. Med.
167:
700-705
|
| 19. | Streilein, J.W., S.F. Grammer, T. Yoshikawa, A. Demidem, and M. Vermeer. 1990. Functional dichotomy between Langerhans cells that present antigen to naive and memory/ effector T lymphocytes. Immunol. Rev. 117: 159-184 [Medline]. |
| 20. |
De Smedt, T.,
B. Pajak,
E. Muraille,
L. Lespagnard,
E. Heinen,
P. De Baetselier,
J. Urbain,
O. Leo, and
M. Moser.
1996.
Regulation of dendritic cell numbers and maturation
by lipopolysaccharide in vivo.
J. Exp. Med.
184:
1413-1424
|
| 21. |
Sallusto, F.,
M. Cella,
C. Danieli, and
A. Lanzavecchia.
1995.
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
J. Exp. Med.
182:
389-400
|
| 22. | Cella, M., F. Sallusto, and A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9: 10-16 [Medline]. |
| 23. | Romani, N., A. Lenz, H. Glassl, H. Stossel, U. Stanzl, O. Majdic, P. Fritsch, and G. Schuler. 1989. Cultured human Langerhans cells resemble lymphoid dendritic cells in phenotype and function. J. Invest. Dermatol. 93: 600-609 [Medline]. |
| 24. |
Larsen, C.P.,
S.C. Ritchie,
T.C. Pearson,
P.S. Linsley, and
R.P. Lowry.
1992.
Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations.
J. Exp. Med.
176:
1215-1220
|
| 25. |
O'Doherty, U.,
R.M. Steinman,
M. Peng,
P.U. Cameron,
S. Gezelter,
I. Kopeloff,
W.J. Swiggard,
M. Pope, and
N. Bhardwaj.
1993.
Dendritic cells freshly isolated from human
blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned
medium.
J. Exp. Med.
178:
1067-1078
|
| 26. | Teunissen, M.B.M., J. Wormeester, S.R. Krieg, P.J. Peters, I.M.C. Vogels, M.L. Kapsenberg, and J.D. Bos. 1990. Human epidermal Langerhans cells undergo profound morphological and phenotypical changes during in vitro culture. J. Invest. Dermatol. 94: 166-173 [Medline]. |
| 27. |
Inaba, K.,
M. Witmer-Pack,
M. Inaba,
K.S. Hathcock,
H. Sakuta,
M. Azuma,
H. Yagita,
K. Okumura,
P.S. Linsley,
S. Ikehara,
S. Muramatsu, et al
.
1994.
The tissue distribution of
the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.
J. Exp. Med.
180:
1849-1860
|
| 28. | Oppenheim, J.J.. 1993. Overview of chemokines. Adv. Exp. Med. Biol. 351: 183-186 [Medline]. |
| 29. | Schall, T.J., and K.B. Bacon. 1994. Chemokines, leucocyte trafficking, and inflammation. Curr. Opin. Immunol. 6: 865-873 [Medline]. |
| 30. |
Rollins, B.J..
1997.
Chemokines.
Blood
90:
909-928
|
| 31. | Baggiolini, M., B. DeWold, and B. Moser. 1994. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 55: 97-179 [Medline]. |
| 32. | Premack, B.P., and T.J. Schall. 1996. Chemokine receptors: gateways to inflammation and infection. Nat. Med. 2: 1174-1178 [Medline]. |
| 33. | Murphy, P.M.. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12: 593-633 [Medline]. |
